Cargando…

Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Mengqin, Peng, Tingting, Wu, Chuanbin, Pan, Xin, Huang, Zhengwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295167/
https://www.ncbi.nlm.nih.gov/pubmed/37370658
http://dx.doi.org/10.3390/bioengineering10060727
_version_ 1785063355860385792
author Guo, Mengqin
Peng, Tingting
Wu, Chuanbin
Pan, Xin
Huang, Zhengwei
author_facet Guo, Mengqin
Peng, Tingting
Wu, Chuanbin
Pan, Xin
Huang, Zhengwei
author_sort Guo, Mengqin
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to the development of IPF, and ferroptosis inhibitors can slow down the occurrence of IPF by chelating iron or reducing lipid peroxidation. For example, the ferroptosis inhibitor deferoxamine (DFO) was used to treat a mouse model of pulmonary fibrosis, and DFO successfully reversed the IPF phenotype and increased the survival rate of mice from 50% to 90%. Given this, we perceive that the treatment of IPF by delivering ferroptosis inhibitors is a promising option. However, the delivery of ferroptosis inhibitors faces two bottlenecks: low solubility and targeting. For one thing, we consider preparing ferroptosis inhibitors into nanomedicines to improve solubility. For another thing, we propose to deliver nanomedicines through pulmonary drug-delivery system (PDDS) to improve targeting. Compared with oral or injection administration, PDDS can achieve better delivery and accumulation in the lung, while reducing the systemic exposure of the drug, and is an efficient and safe drug-delivery method. In this paper, three possible nanomedicines for PDDS and the preparation methods thereof are proposed to deliver ferroptosis inhibitors for the treatment of IPF. Proper administration devices and challenges in future applications are also discussed. In general, this perspective proposes a promising strategy for the treatment of IPF based on inhalable nanomedicines carrying ferroptosis inhibitors, which can inspire new ideas in the field of drug development and therapy of IPF.
format Online
Article
Text
id pubmed-10295167
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102951672023-06-28 Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis Guo, Mengqin Peng, Tingting Wu, Chuanbin Pan, Xin Huang, Zhengwei Bioengineering (Basel) Perspective Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to the development of IPF, and ferroptosis inhibitors can slow down the occurrence of IPF by chelating iron or reducing lipid peroxidation. For example, the ferroptosis inhibitor deferoxamine (DFO) was used to treat a mouse model of pulmonary fibrosis, and DFO successfully reversed the IPF phenotype and increased the survival rate of mice from 50% to 90%. Given this, we perceive that the treatment of IPF by delivering ferroptosis inhibitors is a promising option. However, the delivery of ferroptosis inhibitors faces two bottlenecks: low solubility and targeting. For one thing, we consider preparing ferroptosis inhibitors into nanomedicines to improve solubility. For another thing, we propose to deliver nanomedicines through pulmonary drug-delivery system (PDDS) to improve targeting. Compared with oral or injection administration, PDDS can achieve better delivery and accumulation in the lung, while reducing the systemic exposure of the drug, and is an efficient and safe drug-delivery method. In this paper, three possible nanomedicines for PDDS and the preparation methods thereof are proposed to deliver ferroptosis inhibitors for the treatment of IPF. Proper administration devices and challenges in future applications are also discussed. In general, this perspective proposes a promising strategy for the treatment of IPF based on inhalable nanomedicines carrying ferroptosis inhibitors, which can inspire new ideas in the field of drug development and therapy of IPF. MDPI 2023-06-17 /pmc/articles/PMC10295167/ /pubmed/37370658 http://dx.doi.org/10.3390/bioengineering10060727 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Guo, Mengqin
Peng, Tingting
Wu, Chuanbin
Pan, Xin
Huang, Zhengwei
Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title_full Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title_fullStr Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title_full_unstemmed Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title_short Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
title_sort engineering ferroptosis inhibitors as inhalable nanomedicines for the highly efficient treatment of idiopathic pulmonary fibrosis
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295167/
https://www.ncbi.nlm.nih.gov/pubmed/37370658
http://dx.doi.org/10.3390/bioengineering10060727
work_keys_str_mv AT guomengqin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis
AT pengtingting engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis
AT wuchuanbin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis
AT panxin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis
AT huangzhengwei engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis